Drug-induced movement disorders in children and adolescents

Bibliographys

• JENSEN PS, BHATARA VS, VITIELLO B, HOAG WOOD K, FEIL M, BURKE LB: Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:557–565.
   PubMed Web of Science ®Google Scholar
• ZITO JM, SAFER DJ, DOSREIS S, GARDNER J, BOLES M, LYNCH F: Trends in the prescribing of psychotropic medications to preschoolers. JAMA (2000) 283:1025–1030.
   PubMed Web of Science ®Google Scholar
• ••This paper emphasises the variety andextent of psychotropic medication use in preschool aged children and details the dramatic increase in usage of these agents during the 1990s.
   Google Scholar
• ADAMS S: Prescribing of psychotropic drugs to children and adolescents. Br. Med. J. (1991) 302:217.
   PubMed Web of Science ®Google Scholar
• DEBAR LL, LYNCH F, POWELL J, GALE J: Use of psychotropic agents in preschool children. Arch. Pediatr. Adolesc. Med. (2003) 157:150–157.
   PubMed Web of Science ®Google Scholar
• RUPNIAK NM, JENNER P, MARSDEN CD: Acute dystonia induced by neuroleptic drugs. Psychopharmacology (1986) 88(4):403–419.
   PubMed Web of Science ®Google Scholar
• RUSSELL SA, HENNES HM, HERSON KJ, STREMSKI ES: Upper airway compromise in acute chlorpromazine ingestion. Am. J. Emerg Med. (1996) 14(5):467–468.
   PubMed Web of Science ®Google Scholar
• GARVER DL, DAVIS JM, DEKERMEJIAN H et al.: Dystonic reactions following neuroleptics: time, course and proposed mechanisms. Psychopharmacology (1976) 47:199–201.
   PubMed Web of Science ®Google Scholar
• SIKICH L, HAMER RM, BASHFORD RA, SHEITMAN BB, LIEBERMAN JA: A pilot study of risperidone, olanzapiune, and halopeidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 29(1):133–145.
   PubMed Web of Science ®Google Scholar
• AGUILAR EJ, KESHAVAN MS, MARTINEZ-QUILES MD, HERNANDEZ J, GOMEZ-BENEYTO M, SCHOOLER NR: Predictors of acute dystonia in first-episode psychotic patients. Am. J. Psychiatry (1994) 151(12):1819–1821.
   PubMedGoogle Scholar
• TAIT PA: Supraglottic dystonic reaction to metoclopramide in a child. Med. J. Aust. (2001) 174(10:607–608.
   PubMedGoogle Scholar
• NAJJAR F, PRICE LH: Citalopram and dystonia. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43(1):8–9.
   PubMed Web of Science ®Google Scholar
• RAMOS AE, SHYTLE RD, SILVER AA, SANBERG PR: Ziprasidone-induced oculogyric crisis. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(9):1013–1014.
   PubMed Web of Science ®Google Scholar
• MCCRACKEN JT, MCGOUGH J, SHAH B et al: Risperidone in children with autism and serious behavioral problems. N Engl. J. Med. (2002) 347(5):314–321.
   PubMed Web of Science ®Google Scholar
• ANDERSON LT, CAMPBELL M, GREGA DM, PERRY R, SMALL AM, GREEN WH: Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am. J. Psychiatry (1984) 141(10):1195–1202.
   PubMed Web of Science ®Google Scholar
• FINES RE, BRADY WJ, DEBEHNKE DJ: Cocaine-associated dystonic reaction. Am. J. Emerg Med. (1997) 15(5):513–515.
   PubMed Web of Science ®Google Scholar
• HENDRICKSON RG, MOROCCO AP, GREENBERG MI: Acute dystonic reactions to 'street Xanax'. N Engl. J. Med. (2002) 346(22):1753.
   PubMed Web of Science ®Google Scholar
• KEYSER DL, RODNITZKY RL: Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch. Intern. Med. (1991) 151(4):794–796.
   PubMed Web of Science ®Google Scholar
• CAROFF SN, MANN SC: Neuroleptic malignant syndrome. Psychopharmacol Bull. (1988) 24:24–29.
   Google Scholar
• DALKILIC A. GROSCH WN: Neuroleptic malignant syndrome following initiation of clozpine therapy (letter). Am. J. Psychiatry (1997) 154:881.
   PubMed Web of Science ®Google Scholar
• FILICE GA, MCDOUGALL BC, ERCAN-FANG N, BILLINGTON CJ: Neuroleptic malignant syndrome associated with olanzapine. Ann. Pharmacother. (1998) 32(11):1158–1159.
   PubMed Web of Science ®Google Scholar
• BAJJOKA I, PATEL T, O'SULLIVAN T: Risperidone-induced neuroleptic malignant syndrome. Ann. Emerg Med. (1997) 30(5):698–700.
   PubMed Web of Science ®Google Scholar
• GRAY NS: Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum. Psychopharmacol (2004) 19(3):205–207.
   PubMed Web of Science ®Google Scholar
• ANANTH J, PARAMESWARAN S, GUNATILAKE S, BURGOYNE K, SIDHOM T: Neuroleptic malignant syndrome and atypical antipsychotic drugs. Clin. Psychiatry (2004) 65(4):464–470.
   PubMed Web of Science ®Google Scholar
• KARAGIANIS JL, PHILLIPS LC, HOGAN KP, LEDREW KK: Clozapine-associated neuroleptic malignant syndrome: two new cases and a review the literature. Ann. Pharmacother. (1999) 33(5):623–630.
   PubMed Web of Science ®Google Scholar
• RODNITZKY RL, KEYSER DL: Neurologic complications of drugs. Tardive dyskinesias, neuroleptic malignant syndrome, and cocaine-related syndromes. Psychiatr. Clin. North Am. (1992) 15(2):491–510.
   Google Scholar
• BACA L, MARTINELLI L: Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology (1990) 40:1797–1798.
   PubMed Web of Science ®Google Scholar
• HALMAN M, GOLDBLOOM DS: Fluoxetine and neuroleptic malignant syndrome. Biol. Psychiatry (1990) 28:518–521.
   PubMed Web of Science ®Google Scholar
• FAVA S: Neuroleptic malignant syndrome and lithium carbonate. J. Psychiatry Neurosci. (1995) 20:305–306.
   PubMed Web of Science ®Google Scholar
• EHARA H, MAEGAKI Y, TAKESHITA K: Neuroleptic malignant syndrome and methylphenidate. Pediatr. Neurol (1998) 19:299–301.
   PubMed Web of Science ®Google Scholar
• SACHDEV P, MASON C, HADZI-PAVLOVIC D: Case-control study of neuroleptic malignant syndrome. Am. J. Psychiatry (1997) 154:1156–1158.
   PubMed Web of Science ®Google Scholar
• NAGANUMA H, FUJII I: Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr. Scand. (1994) 90:424–426.
   PubMed Web of Science ®Google Scholar
• HERMESH H, MANOR I, SHILOH R et al.: High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J. Clin. Psychopharmocol (2002) 22(3):252–256.
   PubMed Web of Science ®Google Scholar
• SILVA RR, MUNOZ DM, ALPERT M, PERLMUTTER IR, DIAZ J: Neuroleptic malignant syndrome in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(2):187–194. This is a review of 77 cases of NMS reported in children in the medical literature over a period of 32 years.
   Google Scholar
• SUZUKI A, KONDO T, OTANI K et al.: Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am. J. Psychiatry (2001) 158:1714–1716.
   PubMed Web of Science ®Google Scholar
• KISHIDA I, KAWANISHI C, FURUNO T et al.: Lack of association in Japanese patients between neruoleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. Psychiatr. Genet. (2003) 13(1):55–57.
   PubMed Web of Science ®Google Scholar
• KURLAN R, HAMILL R, SHOULSON I: Neuroleptic malignant syndrome. Clin. Neuropharmacol (1984) 7(2):109–120.
   PubMed Web of Science ®Google Scholar
• VELAMOOR VR, NORMAN RM, CAROFF SN, MANN SC, SULLIVAN KA, ANTELO RE: Progression of symptoms in neuroleptic malignant syndrome. J. Nerv. Ment. Dis. (1994) 182(3):168–173.
   PubMed Web of Science ®Google Scholar
• CAROFF SN: The neuroleptic malignant syndrome. J. Clin. Psychiatry (1980) 41(3):79–83.
   PubMed Web of Science ®Google Scholar
• BALZAN MV: The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity. Postgrad. Med. J. (1998) 74:72–76.
   PubMed Web of Science ®Google Scholar
• WONG MM: Neuroleptic malignant syndrome: two cases without muscle rigidity. Aust. N Z J. Psychiatry (1996) 30(3):415–418.
   PubMed Web of Science ®Google Scholar
• PEIRIS DT, KURUPPUARACHCHI K, WEERASENA LP et al.: Neuroleptic malignant syndrome without fever: a report of three cases. J. NeuroL Neurosurg Psychiatry (2000) 69(2):277–280.
   PubMed Web of Science ®Google Scholar
• CHAN TC, EVANS SD, CLARK RF: Drug-induced hyperthermia. Crit. Care Clin. (1997) 13:785–808.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI N, TANII H, NISHKAWAT et al.: Classification system of complications in neuroleptic malignant syndrome: methods and findings. Exp. Clin. Pharmacol (1997) 19:193–199.
   Web of Science ®Google Scholar
• NARAMOTO A, KOIZUMI N, ITOH N, SHIGEMATSU H: An autopsy case of cerebellar degeneration following lithium intoxication with neuroleptic malignant syndrome. Acta Pathol Jpn (1993) 43:55–58.
   PubMedGoogle Scholar
• SAKAS D, DAVIS JM, HUA J, WANG Z:Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr. Ann. (1991) 21:157–164.
   Web of Science ®Google Scholar
• THOMAS P, MARON M, RASCLE C, COTTENCIN 0, VAIVA G, GOUDEMAND M: Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol. Psychiatry (1998) 43:303–305.
   PubMed Web of Science ®Google Scholar
• ROSEBUSH PI, STEWART T, MAZUREK MF: The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptin useful adjuncts to supportive care? Br. J. Psychiatry (1991) 160:868.
   Google Scholar
• GAITINI L, FRADIS M, VAIDA S, KRIMERMAN S, BENY A: Plasmapheresis in neuroleptic malignant syndrome. Anaesthesia (1997) 52:165–168.
   PubMed Web of Science ®Google Scholar
• SATO Y, ASOH T, METOKI N, SATOH K: Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J. NeuroL Neurosurg. Psychiatry (2003) 74(5):574–576.
   PubMed Web of Science ®Google Scholar
• DAVIS JM, JANICAK PG, SAKKAS P, GILMORE C, WANG Z: Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls. Ther. (1991) 7(2):111–120.
   PubMedGoogle Scholar
• ETAIN B, LEHEUZEY MF, MOUREN-SIMEONI MC: Electroconvulsive therapy in the adolescent: clinical considerations apropos of a series of cases. Can. J. Psychiatry (2001) 46(10):976–981.
   PubMedGoogle Scholar
• TROLLOR JN, SACHDEV PS: Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust. N Z J. Psychiatry (1999) 33(5):650.
   PubMed Web of Science ®Google Scholar
• RUSHTON JL, WHITMIRE JT: Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch. Pediat. Adolesc. Med. (2001) 155:560–565.
   PubMed Web of Science ®Google Scholar
• DUNKLEY EJ, ISBISTER GK, SIBBRITT D, DAWSON AH, WHYTE IM: The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM (2003) 96(9):635–642.
   PubMed Web of Science ®Google Scholar
• •An up-to-date and throrough description of the clinical features and diagnostic criteria for SS.
   Google Scholar
• STERNBACH H: The serotonin syndrome. Am. J. Psychiatry (1991) 148(6):705–713.
   PubMed Web of Science ®Google Scholar
• LANE R, BALDWIN D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J. Clin. Psychopharmacol (1997) 17(3):208–221.
   PubMed Web of Science ®Google Scholar
• MEKLER G, WOGGON B: A case of serotonin syndrome caused by venlafaxine and lithium. Pharmacopsychiamy (1997) 30:272–273.
   PubMed Web of Science ®Google Scholar
• NISIJIMA K, SHIMIZU M, ABET,ISHIGURO T: A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. Int. Clin. Psychopharmacol (1996) 11(4):289–290.
   PubMed Web of Science ®Google Scholar
• GILLMAN PK: Serotonin syndrome: history and risk. Fundam. Clin. Pharmacol (1998) 12:482–491.
   PubMed Web of Science ®Google Scholar
• KAMINSKI CA, ROBBINS MS, WEIBLEY RE: Sertraline intoxication in a child. Ann. Emerg-. Med. (1994) 23(6):1371–1374.
   PubMed Web of Science ®Google Scholar
• HOROWITZ BZ, MULLINS ME: Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr. Emerg-. Care (1999) 15:325–327.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ R, MILLER N: MDMA (ecstasy) and the rave: a review. Pediatrics (1997) 100:705–708.
   PubMed Web of Science ®Google Scholar
• •This review discusses the increasingly important phenomenon of exposure to the street drug, MDMA, among children and adolescents.
   Google Scholar
• DEMIRKIRAN M, JANKOVIC J, DEAN JM: Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin. Neuropharmacol (1996) 19(2):157–164.
   PubMed Web of Science ®Google Scholar
• VUORI E, HENRY JA, OJANPERA I et al.: Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction (2003) 98(3):365–368.
   PubMed Web of Science ®Google Scholar
• •This paper emphasises the potentially serious result of MDMA use in children, especially when combined with other substances.
   Google Scholar
• AGA VM, BARKLAGE NE, JEFFERSON JN(1: Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants. J. Clin. Psychiatry (2003) 64(5):609–611.
   PubMed Web of Science ®Google Scholar
• THOMAS CR, ROSENBERG M, BLYTHE V, MEYER WJ: Serotonin syndrome and linezolid. J. Am. Acad Child Adolesc. Psychiatry (2004) 43(7):790.
   PubMed Web of Science ®Google Scholar
• MATHER NT, TIETJEN GE, LUCKER C: Serotonin syndrome complicating migraine pharmacotherapy. Cephalgia (1996) 16:323–327.
   PubMed Web of Science ®Google Scholar
• GARDNER DM, LYND LD: Sumatriptan contraindications and the serotonin syndrome. Ann. Pharmacother. (1998) 32(1):33–38.
   PubMed Web of Science ®Google Scholar
• PARKER V, WONG AH, BOON HS, SEEMAN MV: Adverse reactions to St. John's Wort. Can. J. Psychiatry (2001) 46(1):77–79.
   PubMed Web of Science ®Google Scholar
• GALA S, CARISMON ML, BAUMGARTNER J: A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy (2003) 23(2):222–230.
   PubMed Web of Science ®Google Scholar
• HUBNER WD, KIRSTE T: Experience with St. John's Wort (hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother. Res. (2001) 15(4):367–370.
   Google Scholar
• LEE DO, LEE CD: Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy (1999) 19(7):894–896.
   PubMed Web of Science ®Google Scholar
• GILLMAN PK: The serotonin syndorme and its treatment. J. Psychopharmacol (1999) 13(1):100–109.
   PubMed Web of Science ®Google Scholar
• MARTIN TG: Serotonin syndrome. Ann. Emerg-. Med. (1996) 28:520–526.
   PubMed Web of Science ®Google Scholar
• GILLMAN PK: Serotonin syndrome treated with chlorpromazine. J. Clin. Psychopharmocol (1997) 17(2):128–129.
   PubMed Web of Science ®Google Scholar
• HARDIE RJ, LEES AJ: Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. j Neurol Neurosurg-. Psychiatr. (1988) 51(6):850–854.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ M, HOCHERMAN S: Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology. CNS Drug (2004) 18(4):213–220.
   PubMed Web of Science ®Google Scholar
• RICHARDSON MA, HAUGLAND G, CRAIG TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors child and adolescent psychiatric patients. Am. J. Psychiatry (1991) 148(10):1322–1328.
   PubMed Web of Science ®Google Scholar
• FACTOR SA, FRIEDMAN JH, LANNON MC, OAKES D, BOURGEOIS K: The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov. Disord. (2001) 16(1):135–139.
   Google Scholar
• FERNANDEZ HH, TRIESCHMANN ME, BURKE MA, JACQUES C, FRIEDMAN JH: Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov. Disord. (2003) 18(5):510–514.
   PubMed Web of Science ®Google Scholar
• MOLHO ES, FACTOR SA: Worsening of motor features of parkinsonism with olanzapine. Mov. Disord. (1999) 14(6):1014–1016.
   PubMed Web of Science ®Google Scholar
• GWINN KA, CAVINESS JN: Risperidone-induced tardive dyskinesia and parkinsonism. Mov. Disord. (1997) 12(1):119–121.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ HH, TRIESCHMANN ME, FRIEDMAN JH: Aripiprazole for drug-induced psychosis in Parkinson's disease: preliminary experience. Clin. Neuropharmacol (2004) 27(1):4–5.
   PubMed Web of Science ®Google Scholar
• CONNEMANN B, SCHONFELDT-LECUONA C: Ziprasidone in Parkinson's disease psychosis. Can. J. Psychiatry (2004) 49(1):73.
   PubMed Web of Science ®Google Scholar
• SACHDEV P: The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr. Bull. (1995) 21(3):431–449.
   PubMed Web of Science ®Google Scholar
• BALDASSANO CF, TRUMAN CJ, NIERENBERG A, GHAEMI SN, SACHS GS: Akathisia: a review and case report following paroxetine treatment. Compr. Psychiatry (1996) 37:122–124.
   PubMed Web of Science ®Google Scholar
• GOGTAY N, SPORN A. ALFARO CL, MULQUEEN A. RAPOPORT JL: Clozapine-induced akathisia in children with schizophrenia. J. Child Adoles. Psychopharmacol (2002) 12(4):347–349.
   PubMed Web of Science ®Google Scholar
• PRUETER C, HABERMEYER B, NORRA C, KOSINSKI CM: Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov. Disord. (2003) 18(0:712–713.
   PubMedGoogle Scholar
• BLAISDELL GD: Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry (1994) 27(4):139–146.
   PubMed Web of Science ®Google Scholar
• FISCHEL T, HERMESH H, AIZENBERG D et al.: Cyproheptacline versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J. Clin. Psychopharmacol (2001) 21(0:612–615.
   PubMedGoogle Scholar
• MILLER CH, FLEISCHHACKER WW: Managing antipsychotic-induced acute and chronic akathisia. Drug Sal' (2000) 22(1):73–81.
   PubMed Web of Science ®Google Scholar
• •This paper provides a useful overview of the medical management of akathisia resulting from the use of antipyschotic agents.
   Google Scholar
• POYUROVSKY M, EPSHTEIN S, FUCHS C, SCHNEIDMAN M, -WEIZMAN R, WEIZMAN A: Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study./ Clin. Psychopharmocol (2003) 23(3):305–308.
   Google Scholar
• HIROSE S, ASHBY CR: Immediate effect of intravenous diazepam in neuroleptic-induced acute akathisia: an open-label study. J. Clin. Psychiatry (2002) 63(6):524–527.
   PubMed Web of Science ®Google Scholar
• SACHDEV P, LONERAGAN C: Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology (1993) 113(1):119–122.
   PubMed Web of Science ®Google Scholar
• ZAATREH M, TENNISON M, D'CRUZ 0, BEACH RL: Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure (2001) 10(8):596–599.
   PubMed Web of Science ®Google Scholar
• SAITO Y, OGUNI H, AWAYA Y, HAYASHI K, OSAWA M: Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatries (2001) 32(5):231–235.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Tardive dyskinesia: pathophysiology and animal models. Clin. Psychiatry (2000) 61 (Suppl. 4):5–9.
   Google Scholar
• CONNOR DF, FLETCHER KE, WOOD JS: Neuroleptic-related dyskinesias in children and adolescents. J. Clin. Psychiatry (2001) 62(12):967–974.
   PubMed Web of Science ®Google Scholar
• •This report emphasises the reduced risk of dyskinesias in children receiving AAP agents compared with those treated with neuroleptic drugs.
   Google Scholar
• KUMRA S, JACOBSEN LK, LENANE M et al.: Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37(2):221–227.
   PubMed Web of Science ®Google Scholar
• ••This paper nicely details the incidence,clinical characteristics, and natural history of TD and WD in neuroleptic-treated paediatric patients with childhood onset schizophrenia.
   Google Scholar
• MCCONVILLE B, CARRERO L, SWEITZER D et al.: Long-term safety, tolerability, and clinical efficacy of quetiapine adolescents: an open-label extension trial. J. Child Adolesc. Psychopharmacol. (2003) 13(1):75–82. 100
   Google Scholar
• CAMPBELL M, ARMENTEROS JL, MALONE RP, ADAMS PB, EISENBERG ZW, OVERALL JE: Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36(6):835–843.
   PubMed Web of Science ®Google Scholar
• GOLDEN GS: Tardive dyskinesia in Tourette syndrome. Pediatr. Neurol. (1985) 1(3):192–194.
   PubMedGoogle Scholar
• REGEUR L, PAKKENBERG B, FOG R, PAKKENBERG H: Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J. Neurol. Neurosurg Psychiatr. (1986) 49(7):791–795.
   PubMed Web of Science ®Google Scholar
• SALLEE FR, KURLAN R, GOETZ CG et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study./ Am. Acad. Child Adolesc. Psychiatry (2000) 39(3):292–299.
   Google Scholar
• MCMAHON WM, FILLOUX FM, ASHWORTH JC, JENSEN J: Movement disorders in children and adolescents. Neurol. Clin. (2002) 20(4):1101–1124.
   PubMed Web of Science ®Google Scholar
• COLLINS KO, COMER JB: Maternal haloperidol therapy associated with dyskinesia in a newborn. Am. J. Health Syst. Pharm. (2003) 60(21):2253–2255.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, WIRSHING WC: Recognition and differential diagnosis of tardive dyskinesia. Int. J. Psychiatry Med. (1989) 19(2):133–144.
   PubMed Web of Science ®Google Scholar
• JESTE DV KRULL AJ, KILBOURN K: Tardive dyskinesia: managing a common neuroleptic side effect. Geriatrics (1990) 45(12):49–54.
   PubMed Web of Science ®Google Scholar
• KANE JM, WOERNER M, LIBERMAN J: Tardive dyskinesia, prevalence, incidence and risk factors. Clin. Psychopharmacol. (1998) 8(Suppl 4):259–262.
   Google Scholar
• JESTE DV, WYATT RJ: In search of treatment for tardive dyskinesia: Review of the literature. Schizophr. Bull. (1979) 5:251–293.
   PubMed Web of Science ®Google Scholar
• GLAZER WM, MORGENSTERN H, SCHOOLER N, BERKMAN CS, MOORE DC: Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiatry (1990) 157:585–592.
   PubMed Web of Science ®Google Scholar
• EGAN MF, APUD J, WYATT RJ: Treatment of tardive dyskinesia. Schizophr. Bull. (1997) 23(4):583–609.
   PubMed Web of Science ®Google Scholar
• SACCHETTI E, VALSECCHI P: Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int. Clin. Psychopharmacol. (2003) 18(6):357–359.
   PubMed Web of Science ®Google Scholar
• O'BRIEN J, BARBER R: Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br. J. Psychiatry (1998) 172:186.
   PubMed Web of Science ®Google Scholar
• LITTRELL KH, JOHNSON CG, LITTRELL S, PEABODY CD: Marked reduction of tardive dyskinesia with olanzapine. Arch. Gen. Psychiatry (1998) 55(3):279–280.
   PubMed Web of Science ®Google Scholar
• EMSLEY R, TURNER HJ, SCHRONEN J, BOTHA K, SMIT R, OOSTHUIZEN PP: A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J. Clin. Psychiatry (2004) 65(5):696–701.
   PubMed Web of Science ®Google Scholar
• FAHN S: A therapeutic approach to tardive dyskinesia. J. Clin. Psychiatry (1985) 46(4 Pt 2):19–24.
   Google Scholar
• ONDO WG, HANNA PA, JANKOVIC J: Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry (1999) 156:1279–1281.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, ORMAN J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology (1988) 38(3):391–394.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, BEACH J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology (1997) 48(2):358–362.
   PubMed Web of Science ®Google Scholar
• BARAK Y, SWARTZ M, SHAMIR E, STEIN D, WEIZMAN A: Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann. Clin. Psychiatry (1998) 10(3):101–105.
   PubMedGoogle Scholar
• ZHANG XY, ZHOU DF, CAO LY, XU CQ, CHEN DA C, WU GY: The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J. Clin. Psychopharmacol. (2004)24(1):83–86.
   PubMed Web of Science ®Google Scholar
• RICHARDSON MA, SMALL AM, READ LL, CHAO HM, CLELLAND JD: Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J. Clin. Psychiatry (2004) 65(1):92–96.
   PubMed Web of Science ®Google Scholar
• • An interesting paper outlining the use of a novel therapy for the treatment of TD in children.
   Google Scholar
• RICHARDSON MA, BEVANS ML, READ LL et al.: Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry (2003) 160(6):1117–1124.
   PubMed Web of Science ®Google Scholar
• THAKER GK, NGUYEN JA, STRAUSS ME, JACOBSON R, KAUP BA, TAMMINGA CA: Clonazepam treatment of tardive dyskinesia: a practical GABA mimetic strategy. Am. J. Psychiatry (1990) 147(4):445–451.
   PubMed Web of Science ®Google Scholar
• UMBRICH P, SOARES KV: Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. (2003)(2).
   Google Scholar
• WONODI I, ADAMI H, SHERR J, AVILA M, HONG LE, THAKER GK: Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J. Clin. Psychopharmacol. (2004) 24(4):441–445.
   PubMed Web of Science ®Google Scholar
• COWEN MA, GREEN M, BERTOLLO DN, ABBOTT K: A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J. Clin. Psychopharmacol. (1997) 17(3):190–193.
   PubMed Web of Science ®Google Scholar
• BURKE RE, YASSA R, JESTE DV, NAIR PV: Neuroleptic-induced movement disorders: a comprehensive survey. Cambridge University Press, New York (1996):409–424.
   Google Scholar
• WIRSHING WC, PHELAN CK, VAN PUTTEN T, MARDER SR, ENGEL J: Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. J. Clin. Psychopharmacol. (1990) 10(5):371–373.
   PubMed Web of Science ®Google Scholar
• KIRIAKAKIS V, BHATIA KP, QUINN NP, MARSDEN CD: The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain (1998) 121\(Pt 11):2053–2066.
   Google Scholar
• •• A thorough review of the clinical features and natural history of TD based on a long-term study over 100 cases.
   Google Scholar
• BURKE RE, KANG UJ: Tardive dystonia: clinical aspects and treatment. Adv. Neurol. (1988) 49:199-210.133. BRASHEAR A, AMBROSIUS WT, ECKERT GJ, SIEMERS ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov. Disord. (1998) 13(1):158–161.
   Google Scholar
• TROTTENBERG T, PAUL G, MEISSNER W, MAIER-HAUFF K, TASCHNER C, KUPSCH A: Pallidal and thalamic neurostimulation in severe tardive dystonia. J. Neurol. Neurosurg. Psychiatr. (2001) 70(4):557–559.
   PubMedGoogle Scholar